MANGOCEUTICALS, INC. (MGRX)
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Sector: Services-Misc Health & Allied Services, NEC
Industry: Medical - Healthcare Information Services
Mangoceuticals, Inc.
NASDAQ:MGRXHealthcare · Medical - Healthcare Information Services
-0.19%$0.1600
CLOSED · Nov 17Prev close$0.1603-0.19%Close$0.1600+3.37%AH close$0.1654
AH$0.1654+3.38%vs close
Mkt Cap$3.56M
EV$2.38M
Float17.27M
O/S22.22M
VOL409K sh
$ Vol$65K
RVOL0.52×
Inst Own7.5%
SI0.3%
Net Cash/Sh+$0.05
Dilution
MCap$3.56MFloat17.27MO/S22.22M
Dilution
Financials Summary
Revenue$456K
Net Income-$20.64M
Total Assets$16.09M
Free Cash Flow-$5.85M
Debt & Equity
Debt 2%
Equity 98%
Preferred 0%
Total Debt$308K
Total Equity$15.2M
Preferred Stock$98
Shares Outstanding
Short Interest
No short interest data available.
Split History1 split · 1 reverse
- 1:15Reverse splitOct 16, 202415 shares → 1
Balance Sheet Details
Assets$16.09M
Liabilities$891K
Accounts Receivable$0
Accounts Payable$417K
Inventory$0
PP&E (Net)$310K
Goodwill$0
Intangible Assets$14.23M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $456K | $616K | $731K | $9K | $0 |
| YoY Growth | -26.0% | -15.8% | 8083.2% | - | - |
| Cost of Revenue | $206K | $236K | $300K | $4K | $0 |
| Gross Profit | $250K | $380K | $432K | $5K | $0 |
| Gross Margin | 54.9% | 61.7% | 59.0% | 54.3% | - |
| Research and Development | $0 | $0 | $0 | $0 | $0 |
| Selling, General, and Administrative | $16.72M | $7.9M | $5.42M | $2M | $18K |
| Other | $2.68M | $454K | $4.23M | $0 | $0 |
| Total Operating Expenses | $19.41M | $8.35M | $9.65M | $2M | $18K |
| Operating Income (EBIT) | -$19.15M | -$7.97M | -$9.22M | -$1.99M | -$18K |
| Operating Margin | -4200.5% | -1294.4% | -1260.3% | -22279.7% | - |
| Interest Expense | $104K | $14K | $0 | $6K | $181 |
| Interest Income | $0 | $0 | $6K | $0 | $0 |
| Other Income (Expense) | -$1.49M | -$735K | $6K | -$6K | -$181 |
| Income Before Tax (EBT) | -$20.64M | -$8.71M | -$9.21M | -$2M | -$18K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$20.64M | -$8.71M | -$9.21M | -$2M | -$18K |
| Net Income Margin | -4526.9% | -1413.6% | -1259.4% | -22352.1% | - |
| Supplementary Data | |||||
| EPS | -2.17 | -4.40 | -6.45 | -1.73 | -0.02 |
| Diluted EPS | -2.17 | -4.40 | -6.45 | -1.73 | -0.02 |
| Weighted Average OS | 10.07M | 1.98M | 1.43M | 1.15M | 1.15M |
| EBITDA | -$18.82M | -$7.96M | -$8.09M | -$1.99M | -$18K |
| EBITDA Margin | -4126.1% | -1292.9% | -1106.4% | -22236.5% | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $1.49M | $59K | $739K | $683K | $23K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $1.49M | $59K | $739K | $683K | $23K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $19K | $0 | $0 |
| Other Current Assets | $61K | $17K | $0 | $0 | $0 |
| Total Current Assets | $1.55M | $76K | $818K | $695K | $23K |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $310K | $62K | $215K | $292K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $14.23M | $15.23M | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $17K | $17K | $0 |
| Total Long-Term Assets | $14.54M | $15.29M | $232K | $309K | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $16.09M | $15.37M | $1.05M | $1M | $23K |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $417K | $838K | $141K | $34K | $0 |
| Short-Term Debt | $0 | $150K | $0 | $167K | $39K |
| Current Income Tax Payable | $0 | $0 | $7K | $3K | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $373K | $0 | $0 | $0 |
| Total Current Liabilities | $891K | $1.43M | $211K | $261K | $39K |
| Long-Term Liabilities | |||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $0 | $65K | $129K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $891K | $1.43M | $276K | $389K | $39K |
| Stockholders' Equity | |||||
| Preferred Stock | $98 | $98 | $0 | $0 | $0 |
| Common Stock | $2K | $325 | $2K | $1K | $800 |
| Retained Earnings | -$40.65M | -$20.81M | -$11.23M | -$2.02M | -$18K |
| Comprehensive Income & Other | -$3K | -$10K | $0 | $0 | $0 |
| Other Stockholders' Equity | $55.85M | $34.75M | $12M | $2.63M | $181 |
| Total Equity | $15.2M | $13.95M | $775K | $614K | -$17K |
| Minority Interest | -$2K | -$1K | $0 | $0 | $0 |
| Total Liabilities and Equity | $16.09M | $15.37M | $1.05M | $1M | $23K |
| Supplementary Data | |||||
| Total Debt | $308K | $215K | $129K | $353K | $39K |
| Net Debt | -$1.18M | $156K | -$610K | -$330K | $17K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$20.64M | -$8.71M | -$9.21M | -$2M | -$18K |
| Depreciation & Amortization | $1.72M | $731K | $25K | $4K | $0 |
| Deferred Income Tax | $0 | $0 | $0 | -$152K | $0 |
| Stock-Based Compensation | $1.17M | $249K | $624K | $234K | $0 |
| Changes in Working Capital: | |||||
| Accounts Receivable | -$20K | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $56K | $697K | $107K | $34K | $0 |
| Other Working Capital | $935K | -$36K | -$66K | -$15K | $0 |
| Total Working Capital Change | $970K | $660K | $42K | $19K | $0 |
| Other Non-Cash Items | $10.93M | $2.2M | $1.52M | $547K | $181 |
| Net Cash from Operating | -$5.85M | -$4.86M | -$7M | -$1.35M | -$18K |
| Investing Activities | |||||
| Capital Expenditures | $0 | $0 | -$4K | -$43K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $65K | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $65K | -$4K | -$43K | $0 |
| Financing Activities | |||||
| Debt Repaid | $207K | - | - | - | - |
| Common Stock Issuance | $5.65M | $1.33M | $6.2M | $2M | $800 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | -$802K | $0 | $0 | $0 |
| Other Financing Activities | $1.15M | $802K | $1.02M | $0 | $0 |
| Net Cash from Financing | $7.27M | $4.13M | $7.06M | $2.05M | $40K |
| Forex Effect | $7K | -$10K | $0 | $0 | $0 |
| Net Change in Cash | $1.43M | -$680K | $56K | $660K | $23K |
| Supplementary Data | |||||
| Operating Cash Flow | -$5.85M | -$4.86M | -$7M | -$1.35M | -$18K |
| Capital Expenditure | -$5 | $0 | -$4K | -$43K | $0 |
| Free Cash Flow | -$5.85M | -$4.86M | -$7M | -$1.39M | -$18K |
| Cash at Beginning | $59K | $739K | $683K | $23K | $0 |
| Cash at End | $1.49M | $59K | $739K | $683K | $23K |